Decitabine in Treating Patients With Myelofibrosis (NCT00095784)
A Phase II Study of Decitabine in Myelofibrosis
🩺 Plain-English Summary (8th-Grade Level)
This phase II trial studies the side effects and how well decitabine works in treating patients with myelofibrosis, a cancer of the blood system associated with fibrosis (scar tissue) in the bone marrow that is advanced and for which there is no standard therapy. Decitabine may block the actions of some proteins that are responsible for turning certain genes off in various cancers including myelofibrosis.
Who can join: Review the eligibility criteria below.
Location: University of Chicago Comprehensive Cancer Center — Chicago, Illinois
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (14 Sites)
- University of Chicago Comprehensive Cancer Center — Chicago, Illinois
- Decatur Memorial Hospital — Decatur, Illinois
- NorthShore University HealthSystem-Evanston Hospital — Evanston, Illinois
- Ingalls Memorial Hospital — Harvey, Illinois
- Loyola University Medical Center — Maywood, Illinois
- Illinois CancerCare-Peoria — Peoria, Illinois
- Central Illinois Hematology Oncology Center — Springfield, Illinois
- Southern Illinois University School of Medicine — Springfield, Illinois
- Fort Wayne Medical Oncology and Hematology Inc-Parkview — Fort Wayne, Indiana
- Northern Indiana Cancer Research Consortium — South Bend, Indiana
- University of Maryland/Greenebaum Cancer Center — Baltimore, Maryland
- Oncology Care Associates PLLC — Saint Joseph, Michigan
- Ohio State University Comprehensive Cancer Center — Columbus, Ohio
- Medical College of Wisconsin — Milwaukee, Wisconsin
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Primary Myelofibrosis
- CINC424A2X01B Rollover Protocol — Darlinghurst, New South Wales
- P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk — Los Angeles, California
- Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis — Seattle, Washington
- Study of Canakinumab in Patients With Myelofibrosis — Los Angeles, California
- A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis — Birmingham, Alabama
Explore by condition: All Primary Myelofibrosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.